All In Biotech

NDA 210806 · Msd Merck CO

Pifeltro

Doravirine · Oral · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 30, 2018

Approved uses

4

Original approval plus efficacy supplements

Registered trials

66

23 Phase 3, 9 recruiting

FAERS reports

788

620 serious, 75 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 9, 2026.

PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine [see Clinical Studies (14) ] . PIFELTRO, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. ( 1 )

Mechanism: Doravirine is an antiretroviral drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 27, 2022 Supplement 7 · Efficacy · priority review LabelLetter
  • Oct 10, 2019 Supplement 3 · Efficacy LetterLabel
  • Sep 19, 2019 Supplement 2 · Efficacy LabelLetter
  • Aug 30, 2018 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • PIFELTRO · DORAVIRINE 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Doravirine" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anxiety71
  • pain71
  • emotional distress65
  • anhedonia53
  • death53
  • chronic kidney disease48
  • drug resistance43
  • pathogen resistance42
  • nausea41
  • drug ineffective38
  • treatment noncompliance37
  • off label use34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20111
20165
20186
201949
202079
2021113
2022121
2023146
2024112
202590
202665

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pifeltro (Doravirine)

2024 spending

$78.7M

Beneficiaries

4,774

42,316 claims

Per beneficiary

$16,481

$58.16 per unit

View as table
YearSpending
2020$32,810,913
2021$47,754,416
2022$59,531,704
2023$70,629,257
2024$78,680,588

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 66 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.